Upregulation of hepatic LDLR expression achieved by increasing activity of the transcription factor SREBP2, for example by treatment with statin drugs, is a major mechanism responsible for lowering levels of these atherogenic lipoproteins and reducing risk of cardiovascular disease (1). This evidence concerns the gene LDLR and cardiovascular disorder.